Efficacy and tolerability profile of etoricoxib in patients with osteoarthritis: A randomized, double-blind, placebo and active-comparator controlled 12-week efficacy trial.
about
A turbulent decade for NSAIDs: update on current concepts of classification, epidemiology, comparative efficacy, and toxicityEfficacy of physical therapy for the treatment of lateral epicondylitis: a meta-analysis.Etoricoxib: a highly selective COX-2 inhibitor.The efficacy of duloxetine, non-steroidal anti-inflammatory drugs, and opioids in osteoarthritis: a systematic literature review and meta-analysis.Responder analysis for pain relief and numbers needed to treat in a meta-analysis of etoricoxib osteoarthritis trials: bridging a gap between clinical trials and clinical practiceClinical pharmacology of etoricoxib: a novel selective COX2 inhibitor.Clinical pharmacology of etoricoxib.Emerging trends in the pharmacotherapy of chronic pain.Etoricoxib for arthritis and pain managementEfficacy and safety of etoricoxib compared with NSAIDs in acute gout: a systematic review and a meta-analysis.Reduced incidence of upper gastrointestinal ulcer complications with the COX-2 selective inhibitor, valdecoxib.Does flare trial design affect the effect size of non-steroidal anti-inflammatory drugs in symptomatic osteoarthritis? A systematic review and meta-analysis.Evaluation of the efficacy and safety of etoricoxib compared with naproxen in two, 138-week randomised studies of patients with osteoarthritis.Non-steroidal anti-inflammatory drugs and myocardial infarctions: comparative systematic review of evidence from observational studies and randomised controlled trials.Coxibs versus combination NSAID and PPI therapy for chronic pain: an exploration of the risks, benefits, and costs.Comparison of benefit-risk preferences of patients and physicians regarding cyclooxygenase-2 inhibitors using discrete choice experimentsRisk management profile of etoricoxib: an example of personalized medicinePrevention of NSAID-related upper gastrointestinal toxicity: a meta-analysis of traditional NSAIDs with gastroprotection and COX-2 inhibitors.Impact of non-steroidal anti-inflammatory drugs on cardiovascular risk: Is it the same in osteoarthritis and rheumatoid arthritis?Efficacy and tolerability of naproxen/esomeprazole magnesium tablets compared with non-specific NSAIDs and COX-2 inhibitors: a systematic review and network analyses.Efficacy and safety of etoricoxib in the treatment of osteoarthritis.Relative efficacy and tolerability of etoricoxib, celecoxib, and naproxen in the treatment of osteoarthritis : A Bayesian network meta-analysis of randomized controlled trials based on patient withdrawal.Efficacy of etoricoxib, celecoxib, lumiracoxib, non-selective NSAIDs, and acetaminophen in osteoarthritis: a mixed treatment comparisonComparison of low-dose rofecoxib versus 1000 mg naproxen in patients with osteoarthritis. Results of two randomized treatment trials of six weeks duration.Characterization of etoricoxib, a novel, selective COX-2 inhibitor.Efficacy and safety profile of treatment with etoricoxib 120 mg once daily compared with indomethacin 50 mg three times daily in acute gout: a randomized controlled trial.Etoricoxib improves osteoarthritis pain relief, joint function, and quality of life in the extreme elderly.Gastrointestinal safety of etoricoxib in osteoarthritis and rheumatoid arthritis: A meta-analysis.Non-Steroidal Anti-Inflammatory Drug-Induced Gastro-Duodenal ToxicityLack of effect of antacids on single-dose pharmacokinetics of etoricoxib
P2860
Q24615651-40B575D7-682B-4C57-92DB-405BF124E48BQ26798013-18E759D3-CE2C-4022-8821-3F5D25A26568Q33213983-8A0CBEA2-3389-4287-BD0B-D744584E0EC5Q33556721-FCB0F861-9BA7-43B7-83F4-7AAA8FD6D43CQ33566361-3ED49976-66C4-43F2-8280-5CAC63FA63FEQ34530950-2AEF08A3-3E1D-483B-9A17-AB558C15B1E9Q34570225-40BDB197-534F-4BBB-BD0A-FEBC6CD7F440Q35094653-1948DA16-76E4-4624-B6EC-2CEB1A43C604Q35166773-221BF77E-88C0-4C07-ABD6-B25C1D448AF7Q35671108-7E841D8F-EDC0-4754-A605-9A10A768DB00Q35875744-69035F71-7318-4993-9E3F-3D246A523E3FQ35925230-85160C78-CBFF-421E-89B1-E477045D4E7FQ35954438-BBB63DAE-0704-4499-B224-9A8D310DC59FQ36013803-B7042986-EF1B-4189-8E56-3068A1552304Q36486905-11F6D2F5-2606-433E-87A6-10B54A4A0196Q36861909-112C6C8D-A00E-48C5-9B8A-7BA163A3945BQ37052864-63F0C34E-08E0-46AE-A3B7-42436310EA7AQ37893966-A4879979-2CCA-44EA-AEBA-24CF14C82A98Q38962092-BC3085F0-B1EE-48B1-8243-07A70528B8B7Q38993297-292202AB-A4EB-4586-9FC7-BB44223397C7Q39320502-FA9B4B8F-FB53-4055-9395-C685DE7A6650Q40976343-066CB17F-EF7D-4716-B307-73BB650E876EQ41963113-FAB18885-F9E3-410C-A038-825D33624F88Q44255896-E77108E4-8300-4535-BF61-A2919FCCA06EQ44484802-FDBE593E-B200-4B98-B9D5-8F2B52FFD642Q44762080-B289AB77-220E-4AEE-9C68-D7F4CA8E6FCAQ47756560-3A09A989-8513-436B-A375-A1675082F967Q48269682-C76E3FDD-A335-4536-9CF4-F2AFDF9E01ACQ57169425-CE5F35F2-81B1-4393-A587-4C6102675B6AQ57221140-20B44C5E-97E3-49E5-822A-37E7A31EBE5F
P2860
Efficacy and tolerability profile of etoricoxib in patients with osteoarthritis: A randomized, double-blind, placebo and active-comparator controlled 12-week efficacy trial.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh
2002年學術文章
@zh-hant
name
Efficacy and tolerability prof ...... rolled 12-week efficacy trial.
@en
Efficacy and tolerability prof ...... rolled 12-week efficacy trial.
@nl
type
label
Efficacy and tolerability prof ...... rolled 12-week efficacy trial.
@en
Efficacy and tolerability prof ...... rolled 12-week efficacy trial.
@nl
prefLabel
Efficacy and tolerability prof ...... rolled 12-week efficacy trial.
@en
Efficacy and tolerability prof ...... rolled 12-week efficacy trial.
@nl
P2093
P1476
Efficacy and tolerability prof ...... rolled 12-week efficacy trial.
@en
P2093
Albert T Leung
Alberto E Gallacher
Andre Beaulieu
Brian Sarembock
Gyula Poor
Jennifer Ng
Kerstin Malmstrom
Lisa M Detora
Matilde Sanchez
Ricardo Castro
P356
10.1185/030079902125000282
P407
P577
2002-01-01T00:00:00Z